These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 12036353)
21. Structure-activity relationships of inhibitors derived from 3-amidinophenylalanine. Stürzebecher J; Prasa D; Wikström P; Vieweg H J Enzyme Inhib; 1995; 9(1):87-99. PubMed ID: 8568569 [TBL] [Abstract][Full Text] [Related]
22. Benzylamine-based selective and orally bioavailable inhibitors of thrombin. Lee K; Jung WH; Park CW; Hong CY; Kim IC; Kim S; Oh YS; Kwon OH; Lee SH; Park HD; Kim SW; Lee YH; Yoo YJ Bioorg Med Chem Lett; 1998 Sep; 8(18):2563-8. PubMed ID: 9873581 [TBL] [Abstract][Full Text] [Related]
23. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures. Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407 [TBL] [Abstract][Full Text] [Related]
25. Nonbenzamidine tetrazole derivatives as factor Xa inhibitors. Quan ML; Ellis CD; He MY; Liauw AY; Woerner FJ; Alexander RS; Knabb RM; Lam PY; Luettgen JM; Wong PC; Wright MR; Wexler RR Bioorg Med Chem Lett; 2003 Feb; 13(3):369-73. PubMed ID: 12565931 [TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo activities of oligodeoxynucleotide-based thrombin inhibitors containing neutral formacetal linkages. He GX; Williams JP; Postich MJ; Swaminathan S; Shea RG; Terhorst T; Law VS; Mao CT; Sueoka C; Coutré S; Bischofberger N J Med Chem; 1998 Oct; 41(22):4224-31. PubMed ID: 9784097 [TBL] [Abstract][Full Text] [Related]
27. Rational design, synthesis, and X-ray structure of selective noncovalent thrombin inhibitors. Wagner J; Kallen J; Ehrhardt C; Evenou JP; Wagner D J Med Chem; 1998 Sep; 41(19):3664-74. PubMed ID: 9733491 [TBL] [Abstract][Full Text] [Related]
28. Synthesis of novel thrombin inhibitors. Use of ring-closing metathesis reactions for synthesis of P2 cyclopentene- and cyclohexenedicarboxylic acid derivatives. Thorstensson F; Kvarnström I; Musil D; Nilsson I; Samuelsson B J Med Chem; 2003 Mar; 46(7):1165-79. PubMed ID: 12646027 [TBL] [Abstract][Full Text] [Related]
29. Structure-based understanding of ligand affinity using human thrombin as a model system. Nienaber VL; Mersinger LJ; Kettner CA Biochemistry; 1996 Jul; 35(30):9690-9. PubMed ID: 8703940 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and Evaluation of Spumigin Analogues Library with Thrombin Inhibitory Activity. Žula A; Będziak I; Kikelj D; Ilaš J Mar Drugs; 2018 Oct; 16(11):. PubMed ID: 30373260 [TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitors. Su T; Yang H; Volkots D; Woolfrey J; Dam S; Wong P; Sinha U; Scarborough RM; Zhu BY Bioorg Med Chem Lett; 2003 Feb; 13(4):729-32. PubMed ID: 12639568 [TBL] [Abstract][Full Text] [Related]
33. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor. Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988 [TBL] [Abstract][Full Text] [Related]
34. Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group. Costanzo MJ; Maryanoff BE; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Kauffman JA; Lewis JM; Krishnan R; Tulinsky A J Med Chem; 1996 Aug; 39(16):3039-43. PubMed ID: 8759623 [No Abstract] [Full Text] [Related]
35. New thrombin inhibitors based on D-cha-Pro-derivatives. Steinmetzer T; Batdorsdhjin M; Kleinwächter P; Seyfarth L; Greiner G; Reissmann S; Stürzebecher J J Enzyme Inhib; 1999; 14(3):203-16. PubMed ID: 10445044 [TBL] [Abstract][Full Text] [Related]
36. Structure-activity study of tripeptide thrombin inhibitors using alpha-alkyl amino acids and other conformationally constrained amino acid substitutions. Shuman RT; Rothenberger RB; Campbell CS; Smith GF; Gifford-Moore DS; Paschal JW; Gesellchen PD J Med Chem; 1995 Oct; 38(22):4446-53. PubMed ID: 7473571 [TBL] [Abstract][Full Text] [Related]
37. Structure-based design of novel potent nonpeptide thrombin inhibitors. Hauel NH; Nar H; Priepke H; Ries U; Stassen JM; Wienen W J Med Chem; 2002 Apr; 45(9):1757-66. PubMed ID: 11960487 [TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160 [TBL] [Abstract][Full Text] [Related]
39. From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Hanessian S; Therrien E; Zhang J; Otterlo Wv; Xue Y; Gustafsson D; Nilsson I; Fjellström O Bioorg Med Chem Lett; 2009 Sep; 19(18):5429-32. PubMed ID: 19674897 [TBL] [Abstract][Full Text] [Related]
40. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles. Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]